Todd A. Alonzo, PhD

Professor of Research Population and Public Health Sciences

Group Statistician for Children's Oncology Group

Image of Todd A. Alonzo, PhD
Is this your profile? Click to edit

Overview

Todd Alonzo is a Professor of Research in the Department of Preventive Medicine, University of Southern California. He received his undergraduate degree at the California State Polytechnic University, San Luis Obispo, California in Statistics in 1994 and received both his MS and his PhD in Biostatistics in 1997 and 2000 from the University of Washington, Seattle. Dr. Alonzo’s main areas of research interest are the statistical methods for analysis of biomarkers and medical diagnostic and screening tests, clinical trials, and the design and analysis of pediatric acute myelogenous leukemia studies. He has published over 290 peer-reviewed articles.

Dr. Alonzo has been member of the Editorial Board for Biometrics, Pediatric Blood Cancer, and Biometrical Journal and has acted as a reviewer for 30 scientific journals. He is a member of several Data Safety and Monitoring Boards. Dr. Alonzo was the President of the International Biometric Society Western Northern America Region (WNAR) in 2009. He is a Fellow of the American Statistical Association.

Awards

  • Fellow, American Statistical Association, 2018
  • The International Society for Magnetic Resonance in Medicine: Outstanding Teacher Award, 2017
  • University of Washington: Senior Biostatistics Award, Department of Biostatistics, 2000
  • ENAR Biometrics Society Distinguished Student Paper Award, 1999
  • WNAR Biometrics Society Best Student Oral Presentation, 1999
  • NIH: Predoctoral Cardiovascular Biostatistics Training Grant, 1995

Research Funding

  • Children's Oncology Group Statistics and Data Center
    NIH · U10CA180899 · Apr 15, 2014 – Feb 29, 2032 · Role: Principal Investigator
  • Bias correction optimizes the choice of screening test for early cancer detection
    NIH · R03CA136048 · Sep 1, 2009 – Aug 31, 2012 · Role: Principal Investigator

Publications

  • Enrollment in Children’s Oncology Group’s clinical trials: population-based linkage with the National Childhood Cancer Registry. J Natl Cancer Inst. 2025 Sep 01; 117(9):1868-1874.. View in PubMed
  • Epigenomic diagnosis and prognosis of Acute Myeloid Leukemia. Nat Commun. 2025 Jul 29; 16(1):6961.. View in PubMed
  • Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children’s Oncology Group. J Clin Oncol. 2025 Aug 20; 43(24):2757.. View in PubMed
  • Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia. JAMA Netw Open. 2025 06 02; 8(6):e2516296.. View in PubMed
  • Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children’s Oncology Group. J Clin Oncol. 2025 06 10; 43(17):1961-1971.. View in PubMed
  • DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children’s Oncology Group. Clin Cancer Res. 2025 Mar 03; 31(5):890-898.. View in PubMed
  • Long-read epigenomic diagnosis and prognosis of Acute Myeloid Leukemia. Res Sq. 2024 Dec 12.. View in PubMed
  • Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration. J Clin Oncol. 2025 03 10; 43(8):972-984.. View in PubMed
  • Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting. Clin Trials. 2025 04; 22(2):131-141.. View in PubMed
  • Sociodemographic and Socioeconomic Factors Correlate with Late-Stage Pediatric Hodgkin Lymphoma and Rhabdomyosarcoma: A Report from the Children’s Oncology Group Registries. Cancer Epidemiol Biomarkers Prev. 2024 Oct 02; 33(10):1327-1338.. View in PubMed